Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality

Blood

Volumn 111, Issue 6, 2008, Pages 3257-3265

  Jasperson, Lisa K ^a   Bucher, Christoph ^a   Panoskaltsis Mortari, Angela ^a   Taylor, Patricia A ^a   Mellor, Andrew L ^b   Munn, David H ^b   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 4;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CELL SURVIVAL; COLON MUCOSA; DISEASE SEVERITY; ENZYME ACTIVITY; GRAFT VERSUS HOST REACTION; IMMUNE RESPONSE; INFLAMMATION; INTESTINE EPITHELIUM CELL; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ACUTE DISEASE; ANIMAL; APOPTOSIS; COLON; CYTOLOGY; DONOR; ENZYMOLOGY; GENETICS; LETHAL GENE; LYMPH NODE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHENOTYPE; SENSITIVITY AND SPECIFICITY; SPLEEN; SURVIVAL RATE; T LYMPHOCYTE; UPREGULATION;

ACUTE DISEASE; ANIMALS; APOPTOSIS; COLON; GENES, LETHAL; GRAFT VS HOST DISEASE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPH NODES; MICE; MICE, KNOCKOUT; PHENOTYPE; SENSITIVITY AND SPECIFICITY; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTES; TISSUE DONORS; UP-REGULATION;

EID: 42449097698     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-06-096081     Document Type: Article

References (28)

1. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22:633-642.
2. Fallarino F, Grohmann U, Vacca G, et al. Tcell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9:1069-1077.
3. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191-1193.
4. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312-319.
5. Ueno A, Cho S, Cheng L, et al. Transient upregulation of IDO in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes. Diabetes. 2007;56:1686-1693.
6. Swanson KA, Zheng Y, Heidler KM, Mizobuchi T, Wilkes DS. CDIIc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol. 2004;30:311-318.
7. Liu H, Liu L, Fletcher BS, Visner GA. Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. FASEB J. 2006;20:2384-2386.
8. Gurtner GJ, Newberry RD, Schloemann SR, Mc-Donald KG, Stenson WF. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology. 2003;125:1762-1773.
9. Koide Y, Yoshida A. The signal transduction mechanism responsible for gamma interferoninduced indoleamine 2,3-dioxygenase gene expression. Infect Immun. 1994;62:948-955.
10. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenasedependent Tcell regulatory functions via IFN Type 1 signaling. J Immunol. 2005;175:5601-5605.
11. Jung ID, Lee CM, Jeong Yl, etal. Differential regulation of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells. FEBS Lett. 2007;581:1449-1456.
12. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol. 2004;172:4100-4110.
13. Fallarino F, Asselin-Paturel C, Vacca C, et al. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol. 2004;173:3748-3754.
14. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naiveTcells. J Immunol. 2006;176: 6752-6761.
15. Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol. 2004;61:67-77.
16. Blazar BR, Taylor PA, McElmurry R, et al. Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via in utero or postnatal transfer. Blood. 1998;92:3949-3959.
17. MellorAL, Baban B, Chandler P, et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses Tcell clonal expansion. J Immunol. 2003;171: 1652-1655.
18. Nakamura T, Shima T, Saeki A, et al. Expression of indoleamine 2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 2007;98:874-881.
19. Mellor AL, Chandler P, Baban B, et al. Specific subsets of murine dendritic cells acquire potent Tcell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol. 2004;16:1391-1401.
20. Panoskaltsis-Mortari A, Price A, Hermanson JR, et al. In vivo imaging of graft-vs-host-disease in mice. Blood. 2004;103:3590-3598.
21. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-vs-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005;06:1113-1122.
22. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol. 2002;168:3771-3776.
23. Waldman E, Lu SX, Hubbard VM, et al. Absence of beta7 integrin results in less graft-vs-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 2006;107: 1703-1711.
24. Dutt S, Ermann J, Tseng D, et al. L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-vs-host disease. Blood. 2005;106:4009-4015.
25. Kwidzinski E, Bunse J, Aktas O, et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEBJ. 2005;19:1347-1349.
26. Hayashi T, Beck L, Rossetto C, et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest. 2004;114:270-279.
27. Wolf AM, Wolf D, Rumpold H, et al. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol. 2004; 113:47-55.
28. Steckel NK, Kuhn U, Beelen DW, Elmaagacli AH. Indoleamine 2,3-dioxygenase expression in patients with acute graft-vs-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance? Scand J Immunol. 2003; 57:185-191.